Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2024-03-27 00:00:00 ET · period of report 2024-03-25 · accession 0001415889-24-009271 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-27 | 2024-03-27 | ACAD | DAVIS STEPHEN | CEO, Dir | S - Sale | $17.90 | -17.7K | 118.8K | -13% | -$317.1K |
| D | 2024-03-27 | 2024-03-25 | ACAD | DAVIS STEPHEN | CEO, Dir | A - Grant | $0.00 | +34.7K | 136.6K | +34% | $0 |
| D | 2024-03-27 | 2024-03-25 | ACAD | DAVIS STEPHEN | CEO, Dir | A - Grant | $0.00 | +286.5K | 286.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-27 | S | D | 17,714 | $17.90 | 118,842 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-25 | A | A | 34,666 | $0.00 | 136,556 | D | — | — | (F1) Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-03-25 | A | A | 286,451 | $0.00 | 286,451 | D | $17.84 · — to 2034-03-24 | 286,451 Common Stock | (F3) 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |